G W Torrance

Summary

Affiliation: McMaster University
Country: Canada

Publications

  1. ncbi A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results
    G W Torrance
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    Osteoarthritis Cartilage 10:518-27. 2002
  2. ncbi Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics
    G W Torrance
    Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, Ontario, Canada
    Pharmacoeconomics 9:535-59. 1996
  3. ncbi The Erectile Function Visual Analog Scale (EF-VAS): a disease-specific utility instrument for the assessment of erectile function
    R Casey
    Male Health Centre, Oakville, Ontario, Canada
    Can J Urol 13:3016-25; discussion 3026. 2006
  4. ncbi Development and testing of a utility measure for major, unipolar depression (McSad)
    K J Bennett
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada
    Qual Life Res 9:109-20. 2000
  5. ncbi Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis
    A J Rosner
    Innovus Research Inc, Burlington, Ontario, Canada
    Pharmacoeconomics 14:559-73. 1998
  6. ncbi The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies
    W J Furlong
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ont, Canada
    Ann Med 33:375-84. 2001
  7. ncbi Development and initial validation of a new preference-based disease-specific health-related quality of life instrument for erectile function
    G W Torrance
    McMaster University, Hamilton, ON, Canada
    Qual Life Res 13:349-59. 2004
  8. ncbi Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate
    G W Torrance
    McMaster University, Hamilton, Ontario, Canada
    Rheumatology (Oxford) 43:712-8. 2004
  9. ncbi The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals
    J L Glennie
    J L Glennie Consulting Inc, Orleans, Ontario, Canada
    Pharmacoeconomics 15:459-68. 1999
  10. ncbi A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results
    J P Raynauld
    Department of Medicine, University of Montreal, Quebec, Canada
    Osteoarthritis Cartilage 10:506-17. 2002

Detail Information

Publications14

  1. ncbi A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results
    G W Torrance
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    Osteoarthritis Cartilage 10:518-27. 2002
    ..The cost effectiveness and cost utility of this new therapeutic modality were determined as part of a Canadian prospective, randomized, 1-year, open-label, multicentered trial...
  2. ncbi Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics
    G W Torrance
    Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, Ontario, Canada
    Pharmacoeconomics 9:535-59. 1996
    ..Because the methods are not country specific, the guidelines will be of interest to those in other countries as well as in Canada...
  3. ncbi The Erectile Function Visual Analog Scale (EF-VAS): a disease-specific utility instrument for the assessment of erectile function
    R Casey
    Male Health Centre, Oakville, Ontario, Canada
    Can J Urol 13:3016-25; discussion 3026. 2006
    ..The EF-VAS represents a major advance in the science of health-related quality of life (HRQol) assessment, as it is the first validated ED-specific utility assessment reported in the literature...
  4. ncbi Development and testing of a utility measure for major, unipolar depression (McSad)
    K J Bennett
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada
    Qual Life Res 9:109-20. 2000
    ..To develop and test a direct utility measure (McSad) for major, unipolar depression...
  5. ncbi Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis
    A J Rosner
    Innovus Research Inc, Burlington, Ontario, Canada
    Pharmacoeconomics 14:559-73. 1998
    ..The aim of this study was to evaluate the cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis...
  6. ncbi The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies
    W J Furlong
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ont, Canada
    Ann Med 33:375-84. 2001
    ..General population norm data are available. The widespread use of HUI facilitates the interpretation of results and permits comparisons. HUI is a useful tool for assessing health status and HRQoL in clinical studies...
  7. ncbi Development and initial validation of a new preference-based disease-specific health-related quality of life instrument for erectile function
    G W Torrance
    McMaster University, Hamilton, ON, Canada
    Qual Life Res 13:349-59. 2004
    ..We report on a novel approach to combine in one instrument the strengths of the specific approach, greater disease relevance and responsiveness, with those of preference-based scoring, generalizability through utilities...
  8. ncbi Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate
    G W Torrance
    McMaster University, Hamilton, Ontario, Canada
    Rheumatology (Oxford) 43:712-8. 2004
    ....
  9. ncbi The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals
    J L Glennie
    J L Glennie Consulting Inc, Orleans, Ontario, Canada
    Pharmacoeconomics 15:459-68. 1999
    ....
  10. ncbi A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results
    J P Raynauld
    Department of Medicine, University of Montreal, Quebec, Canada
    Osteoarthritis Cartilage 10:506-17. 2002
    ..Second, to utilize the measures of effectiveness and costs in an economic evaluation (see accompanying manuscript)...
  11. ncbi Cost-effectiveness of Apligraf in the treatment of venous leg ulcers
    R G Sibbald
    University of Toronto, Toronto, Ontario
    Ostomy Wound Manage 47:36-46. 2001
    ..The results come from a model that is based on a series of estimates and assumptions, and accordingly, confirmation of this finding in a prospective study is encouraged...
  12. ncbi Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis
    N Bellamy
    CONROD, Faculty of Health Sciences, University of Queensland, Level 3, Mayne Medical School, Herston Road, Brisbane, Queensland 4006, Australia
    Ann Rheum Dis 64:881-5. 2005
    ..A secondary analysis of a previously conducted one year randomised controlled trial to evaluate the capacity of responder criteria based on the WOMAC index to detect between treatment group differences...
  13. ncbi Effectiveness and safety of repeat courses of hylan G-F 20 in patients with knee osteoarthritis
    J P Raynauld
    Department of Medicine, University of Montreal, Montreal, Quebec, Canada
    Osteoarthritis Cartilage 13:111-9. 2005
    ..Osteoarthritis Cartilage 2002;10:506-17]. The hypotheses tested were whether the single-course and repeat-course subgroups would be superior to appropriate care and not different from each other...
  14. ncbi Letter to the Editor: Reply to the letter by Max I. Hamburger
    J-P Raynauld
    Osteoarthritis Cartilage 13:1037-8; author reply 1039-40. 2005